Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $32.2200 (-4.02%) ($31.9950 - $32.2200) on Mon. Oct. 4, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.66% (three month average) | RSI | 63 | Latest Price | $32.2200(-4.02%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.4% a day on average for past five trading days. | Weekly Trend | TGTX advances 4.3% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(69%) ARKG(65%) IBB(61%) ARKK(60%) IWO(60%) | Factors Impacting TGTX price | TGTX will decline at least -2.33% in a week (0% probabilities). VIXM(-48%) VXX(-39%) UUP(-19%) UNG(-4%) TLT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.33% (StdDev 4.66%) | Hourly BBV | -1.5 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $33.13(-2.75%) | 10 Day Moving Average | $32.63(-1.26%) | 20 Day Moving Average | $31.49(2.32%) | To recent high | -20% | To recent low | 48.6% | Market Cap | $4.081b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |